IDEX Corporation is a global applied solutions provider serving niche markets with mission-critical components for everyday life. The company operates through three reportable segments: Health & Science Technologies, Fluid & Metering Technologies, and Fire & Safety/Diversified Products. Its business activities are carried out through over 50 wholly-owned subsidiaries that design and manufacture specialized components, including precision fluidics, positive displacement pumps, optical components, sealing solutions, and water dispensing systems. Key brands include IDEX Health & Science, Gast, Airtech, Precision Polymer Engineering, and IDEX Intelligent Water. The company serves end markets such as life sciences, semiconductor manufacturing, aerospace, medical, oil and gas, and municipal water infrastructure. IDEX was founded in 1988 as three entrepreneurial manufacturing companies.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Conglomerates Homepage idexcorp.com
Sector Industrials IR page investors.idexcorp.com/overview/default.aspx
Tags
precision fluidics, optical components, sealing solutions, water dispensing, fire safety, pneumatic technologies, microfluidics, material processing, IDEX Health & Science, Gast, Airtech, Precision Polymer Engineering, FTL Seals Technology, IDEX Intelligent Water, iPEK, Envirosight, ADS, CVI Laser Optics, Advanced Thin Films, IDEX Materials Science Solutions, Muon Group, Millux, LouwersHanique, Veco, Tecan, STC Material Solutions, Mott Corporation, thinXXS Microtechnology, Iridian Spectral Technologies, Micro-LAM, BAND-IT, SAM Waterflow System
Press page idexcorp.com/news/news-item

Metrics

Valuation  
Market cap $ 16.746B
Market cap (USD) $ 16.746B
P/E 31.66
PEG —
P/BV 4.17
P/S 4.58
P/OCF 22.25
P/FCF 25.10
Dividend yield 1.2%
Turnover / mcap —
Returns  
ROE 12.4%
ROI 8.3%
ROIC 9.1%
Profit margin 14.0%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) -6.3%
Quality  
Profitable Yes
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity 43.6%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 17
Quality score -5.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 3.458B 3.269B 3.274B 3.182B 2.765B 2.352B 2.495B 2.484B 2.287B 2.113B 2.021B 2.148B 2.024B 1.954B 1.838B 1.513B 1.33B 1.489B 1.359B 1.155B 1.043B 928.297M 797.92M 742.014M 726.947M 704.276M
Net profit 483.2M 505M 596.1M 586.9M 449.4M 377.778M 425.521M 410.573M 337.257M 271.109M 282.807M 279.386M 255.215M 37.63M 193.857M 157.1M 113.391M 131.36M 155.145M 146.671M 109.803M 86.406M 62.352M 54.112M 32.71M 63.445M
Free cash flow 616.8M 603M 626.8M 489.4M 492.6M 517.728M 477.15M 423.256M 388.895M 361.675M 316.545M 319.964M 369.986M 290.373M 182.066M 152.737M 187.473M 196.294M 173.609M 138.92M 121.894M — — — — 71.989M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 177.94 209.29 217.11 228.33 236.32 199.2 172 126.26 131.97 90.06 76.61 77.84 73.85 46.53 37.12 39.07 31.19 22.63 34.97 45.91 — — — — — —
Price performance 12m -0.15 -0.04 -0.05 -0.03 0.19 0.16 0.36 -0.04 0.47 0.18 -0.02 0.05 0.59 0.25 -0.05 0.25 0.38 -0.35 -0.24 — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 273M 294M 314M 298M 288M 355M 431M 419M 461M 512M
↳ YoY growth +4.9% +7.8% +6.6% -5.0% -3.3% +23.1% +21.5% -2.9% +10.0% +11.0%
↳ 5y CAGR +1.5% +2.8% +4.4% +3.1% +2.1% +5.4% +8.0% +6.0% +9.1% +12.2%
Borrowings, current (USD) 2.09M 516,000 966,000 776,000 176,000 0.00 0.00 600,000 101M 700,000
Borrowings, non-current (USD) 1.01B 859M 848M 849M 1.04B 1.19B 1.47B 1.33B 1.86B 1.82B
Lease liabilities (USD) — — 0.00 85.2M 111M 111M 118M 120M 128M 122M
Cash and deposits (USD) 236M 376M 466M 633M 1.03B 855M 430M 534M 621M 580M
Intangible assets (USD) 436M 415M 383M 388M 416M 597M 948M 1.01B 1.28B 1.25B
Right-of-use assets (USD) — — — 82.4M 107M 107M 110M 118M 125M 120M
Net debt (borrowings + leases - cash) (USD) 780M 483M 383M 302M 130M 446M 1.16B 912M 1.47B 1.36B
Cash flow detail
Operating cash flow (USD) 400M 433M 479M 528M 569M 565M 557M 717M 668M 680M
Purchases of property, plant and equipment (USD) -38.2M -43.9M -56.1M -50.9M -51.5M -72.7M -68M -89.9M -65.1M -63.6M
Purchases of intangible assets (USD) 0.00 0.00 -4M 0.00 0.00 — — — — —
Change in receivables (cash effect) (USD) 302,000 -15.8M -23.4M 22.3M 20.9M -49.4M -71.7M 20.5M -16.9M -41.2M
Change in inventories (cash effect) (USD) 32.7M 760,000 -23M -3.32M 36.5M -46.1M -72.4M 66.2M 17.6M -34.2M
Dividends paid (cash effect) (USD) -103M -111M -127M -147M -152M -161M -177M -191M -205M -213M
Share buybacks (cash effect) (USD) -57.3M -29.1M -174M -54.7M -110M 0.00 -148M -24.2M 0.00 -248M
Interest paid (cash effect) (USD) -37.1M -36.8M -36.3M -36.7M -35.2M -36M -37.1M -50.8M -47.4M -72.2M
Income taxes paid (cash effect) (USD) -109M -105M -90.7M -109M -87.2M -118M -176M -200M -171M -135M
Share-based compensation (USD) 20.3M 24.4M 24.8M 27.7M 19.4M 20.4M 21.6M 21.8M 25.8M 27.3M
Operating cash flow before change in receivables (USD) 400M 449M 503M 506M 548M 615M 629M 696M 685M 722M
Free cash flow (OCF - PPE - intangibles) (USD) 362M 389M 419M 477M 518M 493M 489M 627M 603M 617M
Income detail
Research and development expense (USD) 39.4M 42.4M 48M 56.4M 48.2M 50.1M 61.4M 68.4M 67.4M 70M
↳ 5y CAGR +1.8% +3.1% +7.8% +8.9% +7.5% +4.9% +7.7% +7.3% +3.6% +7.7%
Total comprehensive income (USD) 216M 449M 377M 427M 492M 393M 530M 676M 420M 671M
Comprehensive income to owners (USD) 216M 449M 377M 427M 492M 393M 530M 677M 420M 672M
Reported Feb 28, 2019 Feb 28, 2019 Apr 26, 2019 Feb 21, 2020 Feb 25, 2021 Feb 24, 2022 Oct 26, 2023 Feb 22, 2024 Feb 20, 2025 Feb 19, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

For further information: TRADED: NYSE (IEX) EX-99.1 Bull 5 Bear 0 Results

Investor Contact:

Jim Giannakouros, CFA

Vice President, Investor Relations

(847) 313-9506

IDEX REPORTS RECORD THIRD QUARTER RESULTS

Third Quarter Highlights

(All comparisons are against the prior year period unless otherwise noted)

•Record sales of $952 million increased 8% on both a reported and organic basis

•Reported diluted EPS of $1.95 and record adjusted diluted EPS of $2.33 both increased 15%

•Orders of $991 million increased 13% on both a reported and organic basis

•Strategic acquisitions gaining momentum through higher-value applications in advantaged markets

•Returned $129 million to shareholders through dividends and share repurchases

NORTHBROOK, IL, October 28, 2026 - IDEX Corporation (NYSE: IEX) today announced its financial results for the three-month period ended September 30, 2026.

“We are pleased to report another strong quarter, with results ahead of our expectations. This quarter, we delivered both record sales and adjusted EPS while expanding margins and booked nearly $1 billion in orders. Advantaged markets and larger acquired businesses are driving this performance, and momentum is broadening across the rest of the portfolio,” said Eric D.

IDEX Reports Record Third Quarter Results Bull 5 Bear 0 Results

October 28, 2026

Third Quarter Highlights

(All comparisons are against the prior year period unless otherwise noted)

  • Record sales of $952 million increased 8% on both a reported and organic basis
  • Reported diluted EPS of $1.95 and record adjusted diluted EPS of $2.33 both increased 15%
  • Orders of $991 million increased 13% on both a reported and organic basis
  • Strategic acquisitions gaining momentum through higher-value applications in advantaged markets
  • Returned $129 million to shareholders through dividends and share repurchases

NORTHBROOK, Ill.--(BUSINESS WIRE)-- IDEX Corporation (NYSE: IEX) today announced its financial results for the three-month period ended September 30, 2026.

“We are pleased to report another strong quarter, with results ahead of our expectations. This quarter, we delivered both record sales and adjusted EPS while expanding margins and booked nearly $1 billion in orders. Advantaged markets and larger acquired businesses are driving this performance, and momentum is broadening across the rest of the portfolio,” said Eric D. Ashleman, IDEX Corporation Chief Executive Officer and President.

“Our teams continued to execute well as we met our customers’ increasing demand and drove strong incremental margins on the increased volume. Our ability to drive margin expansion during a period of continued inflation demonstrates the strength of our team and the power of 8020. Additionally, 8020 drives each business toward its full potential and provides the right framework for allocating resources and technologies toward the most attractive opportunities for sustainable value creation across IDEX.”

“We are again increasing our full-year financial guidance due to our strong performance year-to-date, with improved visibility and momentum as we close out 2026.”

Outlook(1)

  • Full year organic sales projected to increase 6.5% to 6.8% over the prior year, up from previous guidance of 5% to 6%
  • Full year adjusted diluted EPS of $8.91 to $8.96, up approximately 12% year-over-year at midpoint, up from previous guidance of $8.70 to $8.85

(1) The Company does not reconcile its forward-looking non-GAAP measures to the most directly comparable financial measures calculated in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) because the timing and magnitude of certain items, including future foreign exchange impacts, acquisitions, divestitures, restructuring costs, impairments, tax impacts, and other special items, cannot be reasonably estimated at this time without unreasonable effort. The unavailable information could have a significant impact on U.S. GAAP results.

Consolidated Financial Results

Three Months Ended September 30,
(Dollars in millions, except per share amounts) 2026 2025 Increase (Decrease)
U.S. GAAP Results
Orders $ 991.2 $ 880.3 $ 110.9
Change in reported orders 13%
Net sales 951.7 878.7 73.0
Change in reported net sales 8%
Gross profit 429.5 390.6 38.9
Gross margin 45.1% 44.5% 60 bps
Net income attributable to IDEX 144.1 127.8 16.3
Net income margin 15.1% 14.5% 60 bps
Diluted EPS attributable to IDEX 1.95 1.70 0.25
Cash flows from operating activities 239.5 203.5 36.0
Operating cash flow as a percent of net income 166 % 159 % NM
Non-GAAP Results*
Change in organic orders 13%
Change in organic sales 8%
Adjusted gross profit 430.3 391.2 39.1
Adjusted gross margin 45.2% 44.5% 70 bps
Adjusted net income attributable to IDEX 172.8 152.8 20.0
Adjusted EBITDA 264.8 239.8 25.0
Adjusted EBITDA margin 27.8% 27.3% 50 bps
Adjusted diluted EPS attributable to IDEX 2.33 2.03 0.30
Free cash flow 214.3 188.7 25.6
Free cash flow conversion 124% 123% 100 bps
NM – Not Meaningful
*Each of the items below is a non-GAAP measure. See the definitions of these non-GAAP measures in the section in this release titled “Non-GAAP Measures of Financial Performance” and reconciliations to their most directly comparable GAAP financial measures in the reconciliation tables at the end of this release.
  • Net sales increased primarily as a result of increased organic sales. The increase in organic sales was driven by higher volumes, primarily in our Health & Science Technologies (“HST”) segment, and positive price across the segments.
  • Gross margin and Adjusted gross margin both increased due to volume leverage, net productivity improvements and favorable mix. These increases were partially offset by price/cost headwinds. Adjusted gross margin excludes the impact of restructuring-related charges, consisting primarily of accelerated depreciation related to the anticipated closure of a facility in the HST segment.
  • Both Diluted EPS and Adjusted diluted EPS increased, primarily due to improved operational results discussed above.
  • Cash flows from operating activities and free cash flow both increased compared to the prior year period, primarily due to higher earnings and improved working capital, driven by timing of shipments and collection of receivables during the prior year period, partly offset by higher cash income tax payments in the current year period. These improvements in cash flows from operating activities also benefited free cash flow but were partly offset by higher capital expenditures during the current year period to support continued growth.

Segment Financial Results

Three Months Ended September 30,(1)
(Dollars in millions) 2026 2025 Increase (Decrease)
Health & Science Technologies
Net sales $ 433.5 $ 381.0 $ 52.5
Change in reported net sales 14%
Change in organic sales* 13%
Adjusted EBITDA(2) 124.8 105.4 19.4
Adjusted EBITDA margin 28.8% 27.7% 110 bps
Fluid & Metering Technologies
Net sales $ 327.9 $ 317.1 $ 10.8
Change in reported net sales 3%
Change in organic sales* 4%
Adjusted EBITDA(2) 111.0 106.8 4.2
Adjusted EBITDA margin 33.9% 33.7% 20 bps
Fire & Safety/Diversified Products
Net sales $ 191.5 $ 181.9 $ 9.6
Change in reported net sales 5%
Change in organic sales* 6%
Adjusted EBITDA(2) 54.5 49.3 5.2
Adjusted EBITDA margin 28.5% 27.1% 140 bps
*These are non-GAAP measures. See the definitions of these non-GAAP measures in the section in this release titled “Non-GAAP Measures of Financial Performance” and reconciliations to their most directly comparable GAAP financial measures in the reconciliation tables at the end of this release.
(1) Three month data includes the results of the acquisition of Micro-LAM, Inc. (July 2025) in the HST segment.
(2) Segment Adjusted EBITDA excludes unallocated corporate costs which are included in Corporate and other.

Health & Science Technologies Segment

  • Net sales for the third quarter 2026 increased 14%. Organic sales increased 13% driven by higher volumes primarily due to AI-driven demand for data center power and semiconductor markets, as well as strength in space and defense and positive price.
  • Adjusted EBITDA margin for the third quarter 2026 increased primarily due to volume leverage and favorable mix. These increases were partially offset by higher employee-related costs, including variable compensation and the impact of acquisitions.

Fluid & Metering Technologies Segment

  • Net sales for the third quarter 2026 increased 3%. Organic sales increased 4% primarily driven by positive price. Higher volumes in our businesses serving municipal water, semiconductor and industrial markets were partially offset by lower volumes in our businesses serving chemical, agriculture and energy markets.
  • Adjusted EBITDA margin for the third quarter 2026 increased slightly, reflecting net productivity improvements and volume leverage, mostly offset by unfavorable mix and higher variable compensation.

Fire & Safety/Diversified Products Segment

  • Net sales for the third quarter 2026 increased 5%. Organic sales increased 6% primarily driven by higher volumes in our BAND-IT and Fire & Safety businesses as well as positive price.
  • Adjusted EBITDA margin for the third quarter 2026 increased primarily due to volume leverage, favorable mix and net productivity improvements. These increases were partially offset by price/cost headwinds.

Corporate Costs

Corporate costs included in consolidated Adjusted EBITDA were $25.5 million during the third quarter 2026, up from $21.7 million during the same prior year period primarily driven by higher employee-related costs, including variable compensation.

Other Items

  • Amended and restated our $800 million revolving credit facility to extend the maturity date to September 2031.

Conference Call

IDEX will host its third quarter earnings conference call on Wednesday, October 28, 2026 at 8:00 a.m. CT. The call will be an audio webcast and accessible on the Company's Investor Relations site at https://investors.idexcorp.com . Associated earnings presentation materials will be available on the Company's website prior to the call.

Interested parties can access the conference by dialing 833.461.5787 and using confirmation code 274998795. Please connect five minutes prior to the start of the conference call.

A replay of the earnings call and associated earnings presentation materials will be available on the Company’s website after the call.

Forward-Looking Statements

This news release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may relate to, among other things, the Company’s full year 2026 outlook including expected organic sales and expected adjusted earnings per share and the assumptions underlying these expectations, capital return strategy, anticipated future acquisition behavior and the anticipated benefits and performance of the Company’s recent or future acquisitions, resource and capital deployment and focus and organic and inorganic growth, the Company’s ability to adapt to macroeconomic challenges, anticipated impacts of tariffs and global trade policies and changes in law, anticipated trends in end markets, including expectations regarding future order volumes and order patterns, anticipated growth initiatives and expansions and execution of those growth initiatives and are indicated by words or phrases such as “anticipates,” “estimates,” “plans,” “guidance,” “expects,” “projects,” “forecasts,” “should,” “could,” “will,” “likely to be,” “management believes,” “the Company believes,” “the Company intends” and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this news release.

The risks and uncertainties include, but are not limited to, the following: levels of industrial activity and economic conditions in the U.S. and other countries around the world, including uncertainties in the financial markets; pricing pressures, including inflation and rising interest rates, and other competitive factors and levels of capital spending in certain industries; the impact of severe weather events, natural disasters and public health threats; economic and political consequences resulting from terrorist attacks, wars and global conflicts; the Company’s ability to make acquisitions and to integrate and operate acquired businesses on a profitable basis; cybersecurity incidents; the continued growth of artificial intelligence (“AI”) and any related changes to demand in AI-driven markets served by the Company’s customers; the relationship of the U.S. dollar to other currencies and its impact on pricing and cost competitiveness; political and economic conditions in countries in which the Company operates; developments with respect to trade policy and existing, new or increased tariffs or other similar measures; changes to applicable laws and regulations, including tax laws; interest rates; capacity utilization and the effect this has on costs; labor markets; supply chain conditions; market conditions and material costs; risks related to environmental, social and corporate governance issues, including those related to climate change and sustainability; and developments with respect to contingencies, such as litigation and environmental matters.

Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the “Risk Factors” section included in the Company’s most recent annual report on Form 10-K and the Company’s subsequent quarterly reports filed with the United States Securities and Exchange Commission (“SEC”) and the other risks discussed in the Company’s filings with the SEC. The forward-looking statements included here are only made as of the date of this news release, and management undertakes no obligation to publicly update them to reflect subsequent events or circumstances, except as may be required by law. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information presented here.

About IDEX

IDEX Corporation (NYSE: IEX), a global engineered products company, is comprised of three primary business segments – Health & Science Technologies, Fluid & Metering Technologies, and Fire & Safety/Diversified Products. Thousands of IDEX employees around the world design and manufacture highly engineered components and applied solutions that are vital to the advances of modern life and help IDEX live its purpose – Trusted Solutions, Improving Lives™. From satellite communications to water systems, from medical diagnostic components to emergency rescue tools and more, we collaborate with customers in the most critical industries to develop solutions that make the world better today and into the future. Founded in 1988, IDEX now includes more than 50 dynamic businesses around the world and manufacturing operations in more than 20 countries.

September 28, 2026

NORTHBROOK, Ill.--(BUSINESS WIRE)-- IDEX Corporation (NYSE:IEX) announced today that it will release its third quarter 2026 results on Wednesday, October 28, 2026, prior to market open. An investor conference call and webcast will take place at 8:00 a.m. (CT) that same day with Chief Executive Officer and President Eric Ashleman and Senior Vice President and Chief Financial Officer Sean Gillen.

The webcast and related earnings presentation will be available in listen-only mode on the Company’s Investor Relations website at https://investors.idexcorp.com . To participate by telephone, please dial USA Toll-Free 1-833-461-5787 or International 1-585-542-9983 and use confirmation code 274998795. Telephone participants are asked to connect five minutes prior to the start of the conference call. A webcast replay will be available following the call on the Company’s Investor Relations website.

**About IDEX
**IDEX Corporation (NYSE: IEX), a global engineered products company, is comprised of three primary business segments – Health & Science Technologies, Fluid & Metering Technologies, and Fire & Safety / Diversified Products. Thousands of IDEX employees around the world design and manufacture highly engineered components and applied solutions that are vital to the advances of modern life and help IDEX live its purpose – Trusted Solutions, Improving Lives™. From satellite communications to water systems, from medical diagnostic components to emergency rescue tools and more, we collaborate with customers in the most critical industries to develop solutions that make the world better today and into the future. Founded in 1988, IDEX now includes more than 50 dynamic businesses around the world and manufacturing operations in more than 20 countries. Learn more about the impactful work we do at www.idexcorp.com .

Investor Contact:
Jim Giannakouros, CFA
Vice President, Investor Relations
(847) 313-9506
[email protected]

Source: IDEX Corporation

View All News

Prompts

IDEX Corporation (ticker IEX), listed in United States.

ETFs Holding IDEX Corporation

ETF Weight in ETF Shares Market value As of
ABEQ 2.95% 18,265 $ 4.145M Jun 30, 2026
DAK 2.31% 4,170 $ 970K Nov 18, 2026
BRES 2.10% 55,065 $ 12.81M Nov 18, 2026
TCAL 1.55% 21,962 $ 5.13M Nov 17, 2026
NVIR 1.08% 276 $ 62.638K Jun 30, 2026
BRNY 0.81% 19,271 $ 4.48M Nov 18, 2026
MCDS 0.62% 210 $ 48.844K Nov 17, 2026
HUSV 0.61% 1,509 $ 352.457K Nov 16, 2026
JSTC 0.52% 6,562 $ 1.533M Nov 17, 2026
RCGE 0.49% 2,088 $ 490K Nov 18, 2026
FMDE 0.37% 120,965 $ 27.453M Jun 30, 2026
FEMV 0.31% 73 $ 16.567K Jun 30, 2026
TMSL 0.31% 37,161 $ 8.434M Jun 30, 2026
AIVL 0.30% 5,478 $ 1.243M Jun 30, 2026
TCAF 0.28% 127,270 $ 29.726M Nov 17, 2026
SOVF 0.25% 951 $ 219.158K Jul 31, 2026
FELV 0.23% 32,877 $ 7.461M Jun 30, 2026
FTLS 0.12% 13,866 $ 0.00 Nov 16, 2026
TACU 0.12% 91 $ 21.255K Nov 17, 2026
DFAT 0.11% 149,681 $ 35.629M Nov 12, 2026
IALT short -0.11% -36,222 $ -8.46M Nov 16, 2026
HBTA 0.11% 1,148 $ 262.479K Aug 31, 2026
AVMC 0.10% 2,422 $ 565.707K Nov 16, 2026
FELC 0.09% 31,703 $ 7.195M Jun 30, 2026
AFLG 0.09% 3,744 $ 874.486K Nov 16, 2026
AAUS 0.08% 1,734 $ 400K Nov 18, 2026
DFUV 0.08% 50,697 $ 12.067M Nov 12, 2026
UPAR 0.07% 153 $ 35.736K Nov 17, 2026
GSPY 0.06% 1,880 $ 439.112K Nov 17, 2026
DFSU 0.06% 5,978 $ 1.423M Nov 12, 2026
DXUV 0.05% 13,881 $ 3.304M Nov 12, 2026
DFAC 0.05% 173,335 $ 41.259M Nov 12, 2026
XMAG 0.04% 346 $ 82.358K Nov 13, 2026
RPAR 0.04% 974 $ 227.497K Nov 17, 2026
DCOR 0.04% 67,115 $ 15.975M Nov 12, 2026
MSLC 0.03% 6,102 $ 1.395M Aug 31, 2026
LGDX 0.03% 175 $ 40.875K Nov 17, 2026
DFAU 0.03% 15,961 $ 3.799M Nov 12, 2026
DFUS 0.03% 22,920 $ 5.456M Nov 12, 2026
HCMT 0.02% 513 $ 118.221K Jul 31, 2026
DFLV 0.02% 6,720 $ 1.6M Nov 12, 2026
VSLU 0.02% 493 $ 111.886K Jun 30, 2026
DFVX 0.01% 319 $ 75.932K Nov 12, 2026
EBI 0.01% 349 $ 79.795K Aug 31, 2026
CSHP 0.01% 147 $ 34.335K Nov 16, 2026
AVSU 0.01% 283 $ 66.1K Nov 16, 2026
DFAS 0.00% 2,611 $ 621.496K Nov 12, 2026
AVUS 0.00% 71 $ 16.583K Nov 16, 2026
AVLC 0.00% 18 $ 4,204.26 Nov 16, 2026
CORO 0.00% 46 $ 10.859K Nov 16, 2026
LCTU 0.00% 2 $ 467.14 Nov 16, 2026
SHRT 0.00% 1 $ 233.57 Nov 17, 2026